tailieunhanh - Báo cáo y học: "Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. | Kim et al. Journal of Hematology Oncology 2011 4 34 http content 4 1 34 JOURNAL OF HEMATOLOGY ONCOLOGY RESEARCH Open Access Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma NOS treated with anthracycline-containing chemotherapy 1 1 1 2 2 2 3 Yu Ri Kim Jin Seok Kim Soo Jeong Kim Hyun Ae Jung Seok Jin Kim Won Seog Kim Hye Won Lee Hyeon Seok Eom3 Seong Hyun Jeong4 Joon Seong Park4 June-Won Cheong 1 and Yoo Hong Min1 Abstract Background Peripheral T-cell lymphoma not otherwise specified PTCL-NOS is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results Thirty-six patients had a low absolute lymphocyte count ALC X 109 L at diagnosis. Patients with lymphopenia had shorter overall survival OS and progression-free survival PFS rates compared with patients with high ALCs P P respectively . In multivariate analysis high-intermediate high-risk International Prognostic Index IPI scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was in the low ALC group and in the high ALC group P . In patients considered high-intermediate high-risk based on IPI scores lymphopenia was also associated with shorter OS and PFS P P respectively . Conclusion This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores. Keywords peripheral T-cell lymphoma not otherwise specified lymphopenia international .